For the first time, certain immunosuppressant drug (ISD) assays can now be performed automatically on cobas modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays on a single platform.
The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory.
Tacrolimus and cyclosporine are important ISDs used in the maintenance therapy of transplant recipients. Owing to the significant pharmacokinetic variability between patients for these drugs, TDM and concentration-controlled dosing are used to tailor therapy for individual patients, ensuring the ideal balance between efficacy and toxicity. It is therefore paramount that tests used to monitor a transplant patient’s response to therapy exhibit high-quality performance and are efficient to run.
The tests can be performed on any of the cobas modular platforms, allowing a wide range of assays to be performed on a single analytical platform.
www.roche.com